Loading...
Loading...
Browse drug and medication recalls including prescription drugs, OTC medications, and supplements. Stay informed about pharmaceutical safety alerts.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.
Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection, USP, 20 million Unit. The vials contained Cefozalin
Labeling: Label Mix-Up; Some vials of Cefazolin for Injection, USP 1 gram were incorrectly labeled as penicillin G potassium for Injection, USP, 20 million Unit
Failed Impurity/Degradation Specifications
Failed Impurity/Degradation Specifications
This recall involves three types of California Gold Nutrition dietary supplements: Daily Prenatal Multi, Ultamins Women's Multivitamin, and Ultamins Women's 50+ Multivitamin. The California Gold Nutrition Daily Prenatal Multivitamin bottles are white with a white lid and a gold border label. The bottle contains 60 fish gelatin softgel dietary supplements. The California Gold Nutrition Women's Multivitamin and Women's 50+ Multivitamin both have dark purple packaging with a gold border label. Both products contain 60 capsules in foil within the packaging. The following batch numbers and expiration dates for the products are printed on the back of the package near the bottom of package/sleeve. Products Batch Codes Expiration Dates Daily Prenatal Multi 2307050A, 2404096A, 2411100A 08/2025, 05/2026, 11/2026 Ultamins Women's Multivitamin V0532, V0533 11/2026, 07/2026 Ultamins Women's 50+ Multivitamin V0534, V0536 07/2026, 11/2026
Downstream recall of a dietary supplement ingredient that was manufactured out of specification.
Downstream recall of a dietary supplement ingredient that was manufactured out of specifications.
Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Subpotent Drug: Assay below the approved specification
Defective container; blister packaging inadequately sealed.